An update from MIRA Pharmaceuticals, Inc. (MIRA) is now available.
MIRA Pharmaceuticals has approved a significant amendment to CEO Erez Aminov’s employment agreement, boosting his annual salary to $300,000 from June 1, 2024. The new terms also outline generous severance benefits, including a full year’s salary and accelerated vesting of stock options in case of termination without cause or resignation for a good reason. These provisions are further enhanced if the termination occurs within 18 months following a change of control of the company, emphasizing the company’s commitment to compensating its top executive fairly during periods of transition.
See more data about MIRA stock on TipRanks’ Stock Analysis page.
